Product Description
Cimetidine is used to treat ulcers; gastroesophageal reflux disease (GERD), a condition in which backward flow of acid from the stomach causes heartburn and injury of the food pipe (esophagus); and conditions where the stomach produces too much acid, such as Zollinger-Ellison syndrome. Over-the-counter cimetidine is used to prevent and treat symptoms of heartburn associated with acid indigestion and sour stomach. Cimetidine is in a class of medications called H2 blockers. It decreases the amount of acid made in the stomach. (Sourced from: https://medlineplus.gov/druginfo/meds/a682256.html)
Mechanisms of Action: H2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Denmark | Dominican Republic | Ecuador | Egypt | France | Germany | Greece | Hong Kong | India | Indonesia | Ireland | Italy | Jordan | Korea | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovenia | South Africa | Sweden | Taiwan | Tunisia | Turkey | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Neuralgia, Postherpetic|Neuritis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HSK16149-105 | P1 |
Completed |
Neuritis |
2023-04-24 |
43% |
| CTR20230734 | P1 |
Not yet recruiting |
Neuralgia, Postherpetic |
None |